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Introduction: Mycobacterium abscessus and Mycobacterium 
massiliense are grouped as the Mycobacterium abscessus 
complex. Although M. massiliense lung diseases are reported to 
have better treatment response than M. abscessus lung diseases, 
clinical comparisons between these two species remain limited. 
The aim of this study was to elucidate the differences between 
M. abscessus lung diseases and M. massiliense lung diseases in 
terms of progression rate, treatment outcomes, and the 
predictors thereof. 
 
Methods: Between January 1, 2006 and June 30, 2015, 56 
patients and 54 patients were diagnosed with M. abscessus and 
M. massiliense lung diseases, respectively. The time to 
progression requiring treatment and treatment outcomes were 
compared between the two groups of patients, and predictors of 
progression and sustained culture conversion with treatment 
were analyzed. In addition, mediation analysis was performed to 




Results: During follow-up, 21 of 56 patients with M. abscessus 
lung diseases and 21 of 54 patients with M. massiliense lung 
diseases progressed requiring treatment. No difference was 
detected in the time to progression between the two patient 
groups. Lower body mass index, bilateral lung involvement, and 
fibrocavitary type disease were identified as predictors of 
disease progression. Among the patients who began treatment, 
infection with M. massiliense rather than M. abscessus and the 
use of azithromycin rather than clarithromycin were associated 
with sustained culture conversion, while lower body mass index 
was a negative predictive factor. The difference in treatment 
outcomes between these two species was partly mediated by the 
organism’s susceptibility to clarithromycin.  
 
Conclusions: Progression rates were similar but treatment 
outcomes differed significantly between patients with lung 
disease caused by M. abscessus and M. massiliense. This 
difference in treatment outcomes was partly explained by the 
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Nontuberculous mycobacteria (NTM) comprise mycobacterial 
species other than those of Mycobacterium tuberculosis complex 
and Mycobacterium leprae. Although determining the incidence 
and prevalence of NTM lung diseases remains challenging, 
recent epidemiologic reports indicate that the prevalence of NTM 
lung diseases is increasing, especially in many developed 
countries [1-4].  
The Mycobacterium abscessus complex, one of the rapid 
growing NTM, is an important cause of chronic pulmonary 
infection [2, 3, 5]. Although there is a significant variability in 
geographic distribution, M. abscessus complex is the most 
common cause of pulmonary infection worldwide among the rapid 
growing NTM [6]. In South Korea, the M. abscessus complex is 
the second-most common pathogen responsible for NTM lung 
diseases after the Mycobacterium avium complex (MAC) [7]. 
Currently, the M. abscessus complex comprises three different 
species (M. abscessus, M. massiliense, and M. bolletii) based on 
gene sequence analysis.  
Treatment outcomes for M. abscessus complex lung diseases 
vary significantly with culture conversion rates ranging from 40% 
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to 80% according to previous reports [8-10]. This variance in 
treatment outcomes may be due to the heterogeneity in 
treatment strategies employed and the different proportions of 
M. abscessus and M. massiliense in each study population [11]. 
M. abscessus is known to be more resistant to antibiotics [12] 
and to carry a worse prognosis compared with M. massiliense 
[13-16]. However, few studies have reported a detailed 
comparison of the clinical characteristics of lung disease caused 
by M. abscessus and M. massiliense.  
The aim of this study was to elucidate the differences in 
progression rate, treatment outcomes, and the predictors thereof 
between M. abscessus lung diseases and M. massiliense lung 
diseases. In addition, we evaluated whether susceptibility to 










MATERIALS AND METHODS 
1. Study Population  
We retrospectively reviewed the medical records of patients 
diagnosed as having a lung disease caused by M. abscessus 
complex at the Seoul National University Hospital between 
January 1, 2006 and June 30, 2015. We excluded patients with a 
follow-up period of less than 6 months. Patients who did not 
undergo chest computed tomography (CT) or who had malignant 
diseases at stage IV were also excluded. The protocol of this 
study was approved by the institutional review board of Seoul 
National University Hospital. 
 
2. Microbiologic evaluation 
Acid-fast bacilli (AFB) smear and mycobacterial cultures 
were performed as recommended in the standard guidelines [17, 
18]. All cultures were grown in both solid Ogawa media and the 
BACTEC MGIT 960 system. NTM species were identified by 
gene sequence analysis of the 16S rRNA gene using the 
algorithm described in the Clinical and Laboratory Standards 
Institute (CLSI) guidelines [19]. Sequencing of the rpoB and tuf 
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genes was performed for further identification. In particular, 
differentiation between M. abscessus and M. massiliense was 
performed based on analysis of the rpoB gene sequence [20, 21]. 
Antimycobacterial drug susceptibility tests were referred to 
the Korean Institute of Tuberculosis and performed using broth 
microdilution. Minimum inhibitory concentrations (MICs) of 
antibiotics (i.e. amikacin, cefoxitin, ciprofloxacin, clarithromycin, 
imipenem, moxifloxacin) were determined according to the CLSI 
guideline as well [22]. Determining the MIC of azithromycin is 
difficult due to its poor solubility at high concentrations, so 
instead the MIC of clarithromycin was determined as being 
representative of this class of macrolides [23]. Isolates were 
regarded as susceptible if the MIC of clarithromycin was 2 μg/mL 
or less, and as resistant if the MIC of clarithromycin was 8 μg/mL 
or greater. Isolates with an MIC between 2 and 8 μg/mL were 
regarded as having an intermediate level of resistance. 
Susceptibility to clarithromycin was evaluated after 3 and 14 
days of incubation to detect resistance. If isolates were 
susceptible after 3 days of incubation and resistant after 14 days 




3. Radiographic evaluation 
The CT scan images obtained at the time of diagnosis of M. 
abscessus complex lung disease were reviewed as the baseline 
CT in terms of radiographic extents (laterality and number of 
involved lobes) and disease patterns (i.e. either nodular 
bronchiectatic or fibrocavitary type) [14, 18]. Follow-up CT 
examinations were typically performed every 6 months to 1 year 
and as needed according to the decision of duty physician. 
 
4. Diagnosis of NTM lung disease 
Patients were diagnosed with M. abscessus complex lung 
diseases based on the diagnostic criteria of American Thoracic 
Society (ATS)/Infectious Diseases Society of America (IDSA) 
guideline [18]. Because strains of both M. abscessus and M. 
massiliense were isolated in some patients, patients were 
classified into three groups: M. abscessus lung diseases, M. 
massiliense lung diseases, and M. abscessus/M. massiliense 
mixed lung diseases. Patients with M. abscessus/M. massiliense 
mixed lung diseases were defined as those who had more than 
two positive cultures for both M. abscessus and M. massiliense. 
Additionally, patients were considered to have co-infection with 
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NTM species other than M. abscessus complex if those NTM 
species were isolated at least twice. 
 
5. Treatment protocol 
Patients underwent follow-ups every 3 to 6 months and 
treatment was offered in cases of significant radiographic 
progression (i.e. new cavity formation), or worsening 
respiratory symptoms (i.e. development of hemoptysis). For this 
study, patients were defined as having disease progression if 
treatment was offered to them. Once patients had agreed a 
course of treatment, they were hospitalized and central catheters 
were peripherally inserted for long-term parenteral therapy. 
Patients received combination antibiotic therapy including one 
macrolide agent (clarithromycin or azithromycin) and at least 
two parenteral agents such as amikacin, cefoxitin, or imipenem.  
Patients were hospitalized for at least three weeks. The 
decision whether to discharge was made by the duty physician, 
taking account of symptomatic and radiographic improvements. 
After discharge, macrolide treatment was continued with 
concurrent outpatient parenteral antibiotic therapy comprising 
amikacin three or five times a week via peripherally-inserted 
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central catheters. The duration of amikacin administration was 
not predefined and patients continued to receive amikacin until 
either clinical improvement or the development of significant 
adverse events was observed. 
 
6. Treatment response assessment 
Culture conversion was defined as the production of three 
consecutive negative cultures from sputum specimens. If 
patients could not expectorate sputum after one or two 
consecutive negative cultures, they were also regarded as having 
culture conversion. Final treatment responses were classified as 
either sustained culture conversion or as treatment failure. 
Treatment failure included failure of achieving culture 
conversion, or recurrence after initial culture conversion. If 
patients could not be followed-up before culture conversion, 
they were regarded as having treatment failure. 
 
7. Statistical analysis 
Data were summarized as means with standard deviations for 
continuous variables with normal distribution, or medians with 
interquartile range (IQR) for those with non-normal distribution. 
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For categorical variables, values were reported as frequencies 
and proportions. Differences between groups were analyzed 
using Student’s t-test, Mann-Whitney test, Pearson’s chi-
square test, or Fisher’s exact test, as appropriate. P values less 
than 0.05 were considered statistically significant in a two-tailed 
test.  
Time to progression was compared between patients with M. 
abscessus and M. massiliense lung diseases using the Kaplan-
Meier method. To elucidate risk factors for progression, 
multivariable logistic regression was performed. Among patients 
who started treatment, a comparison of the time to initial culture 
conversion between patients with M. abscessus and M. 
massiliense lung diseases was performed using the Kaplan-
Meier method. Multivariable logistic regression was also used to 
determine predictors of sustained culture conversion. In both 
logistic regression models, variables with P values less than 0.1 
in the univariable analysis were included in the multivariable 
analysis and adjusted odds ratios (aORs) with 95% confidence 
intervals (CI) were calculated.  
In addition, we performed mediation analysis to evaluate 
whether susceptibility to clarithromycin could explain the 
9 
 
different treatment outcomes observed for M. abscessus and M. 
massiliense lung disease (Figure 1) [24]. Binary mediation with 
bootstrapping (500 replications) was used to estimate the direct 
effect (effect of the predictor on the outcome by itself) and the 
indirect effect (effect of the predictor on the outcome via the 
mediator) with CIs, as described in previous studies of similar 
design [25]. Where the CI of the indirect effect does not cross 
zero, such analysis can provide evidence of significant mediation. 
We also adjusted the model by including other variables 
significantly associated with sustained culture conversion as 
covariates. All the statistical analyses were carried out using 













Figure 1. Mediation analysis for determining whether 
susceptibility to clarithromycin mediates the different treatment 
outcomes between M. abscessus and M. massiliense lung 
diseases.   
This process was composed of a series of separate regression 
models to examine three effects: the effect of the NTM species 
(M. abscessus or M. massiliense) on sustained culture 
conversion (pathway c), the effect of the NTM species on 
susceptibility to clarithromycin (pathway a), and the effect of the 
NTM species on sustained culture conversion after accounting 






1. Characteristics of patients 
During the study period, a total of 143 patients were identified 
from whom M. abscessus complex had been isolated at least once. 
Thirty patients were excluded because they did not meet the 
ATS/IDSA criteria for NTM lung disease. The remaining 113 
patients with M. abscessus complex lung diseases were 
classified into three predefined groups: 56 patients had M. 
abscessus lung diseases, 54 patients had M. massiliense lung 
diseases, and the remaining three patients had M. abscessus/M. 
massiliense mixed lung diseases. These three patients were not 
included in the main analyses of the current study. Subsequently, 
a total of 110 patients were analyzed (Figure 2). 
The median age of patients with M. abscessus lung diseases 
and those with M. massiliense lung diseases was similar at 64 
and 63 years, respectively (P = 0.990). The proportion of female 
patients was also similar (66.1% vs. 63.0%, respectively, P = 
0.733). Less than one-fifth of patients (17.9% of M. abscessus 
and 18.5% of M. massiliense) showed a fibrocavitary pattern of 
disease. MAC was the most common species of co-infected 
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NTM (21 of 23 in the M. abscessus group and 15 of 17 in the M. 
























Figure 2. Selection of study patients.   
Among 143 patients from whom M. abscessus complex had been 
isolated at least once during the study period, 113 patients met 
the ATS/IDSA criteria for NTM lung disease. They were 
classified into three predefined groups as follows: 56 patients 
with M. abscessus lung diseases, 54 patients with M. massiliense 
lung diseases, and three patients with M. abscessus/M. 







Table 1. Baseline characteristics of patients with M. abscessus 
and M. massiliense lung diseases 
Characteristics 
M. abscessus 
(N = 56) 
M. massiliense 
(N = 54) 
P value 
Age, years 64 (57–70) 63 (52–71) 0.990 
Female 37 (66.1%) 34 (63.0%) 0.733 
BMI, kg/m2 20.6 ± 2.6 20.8 ± 2.8 0.678 











































  Bilateral involvement 
  No. of involved lobes 
Disease pattern 
  Nodular bronchiectatic 






















Initial AFB smear positivity 14 (25.0%) 12 (22.2%) 0.732 
Co-infection with other NTM 23 (41.1%) 17 (31.5%) 0.296 
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; CKD, chronic kidney disease; AFB, acid-fast bacilli; NTM, 
nontuberculous mycobacteria 
Data are shown as mean ± SD for normally distributed data, median (IQR) for 







2. In vitro drug susceptibility 
The results of an in vitro antimicrobial susceptibility test were 
available for 95 patients (Table 2). A significant difference in the 
susceptibility to clarithromycin between M. abscessus and M. 
massiliense was identified (P < 0.001). Although 38 out of 46 
(82.6%) strains of M. massiliense isolated were susceptible to 
clarithromycin, only 16 out of 49 (32.6%) strains of M. 
abscessus were susceptible. Inducible resistance was observed 
in 27 (55.1%) strains of M. abscessus isolated and in three (6.5%) 















(N = 49) 
M. massiliense 






Inducible resistance, % 
MIC at day 3, μg/mL 


























































































































Abbreviations: MIC, minimum inhibitory concentration 
Data are shown as median (IQR) and number (%) as indicated.  
Drug susceptibility tests were available for 49 of 56 (87.5%) patients from the 





3. Disease progression rate 
During the follow-up period (median 1,265 days; IQR 664–
1,938), disease progression necessitated treatment of 21 of the 
56 (37.5%) patients with M. abscessus lung diseases and 21 of 
the 54 (38.9%) patients with M. massiliense lung diseases (P = 
0.881). There was no difference in time to progression between 
M. abscessus and M. massiliense lung diseases (Figure 3, P = 
0.941). Lower body mass index (BMI) (aOR 4.8; 95% CI 1.4–
16.5), bilateral lung involvement (aOR 3.8; 95% CI 1.1–13.8), and 
fibrocavitary type disease (aOR 3.6; 95% CI 1.1–12.8) were 
identified as risk factors for disease progression. The probability 
of disease progression did not differ between M. abscessus and 
M. massiliense lung diseases after adjusting for these factors 












Figure 3. Kaplan-Meier analysis of the comparison of time to 
disease progression between M. abscessus and M. massiliense 
lung diseases.   
There was no difference in time to progression between M. 










Table 3. Clinical characteristics associated with disease 
progression requiring treatment among 110 patients with M. 
abscessus or M. massiliense lung disease 
 Unadjusted Adjusted 
Variables 
Odds ratio  
(95% CI) 
P value 











































































































































Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 




4. Treatment outcomes 
Among the 42 patients who displayed disease progression, 36 
patients (19 with M. abscessus lung diseases and 17 with M. 
massiliense lung diseases) agreed to commence treatment. 
Macrolide treatment with parenteral agents including amikacin, 
cefoxitin, or imipenem was initiated in 16 patients (84.2%) with 
M. abscessus lung diseases and in 13 patients (76.5%) with M. 
massiliense lung diseases. Surgical resection was included for 
three patients (15.8%) with M. abscessus lung diseases and two 
patients (11.8%) with M. massiliense lung diseases (Table 4).  
Patients with M. massiliense lung diseases were significantly 
more likely to achieve initial culture conversion (Figure 4, P = 
0.045). However, recurrence occurred in 6 out of 11 patients 
with M. abscessus lung disease who achieved initial culture 
conversion, while no recurrence was observed in 14 patients 
with M. massiliense lung disease. Consequently, sustained 
culture conversion was more common in patients with M. 
massiliense lung diseases than those with M. abscessus lung 
diseases (82.4% vs. 26.3%, P = 0.001). Being infected with M. 
massiliense rather than M. abscessus (aOR 17.2; 95% CI 2.2–
136.9) and use of azithromycin rather than clarithromycin (aOR 
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9.0; 95% CI 1.1–74.7) were identified as predictors of sustained 
culture conversion, while BMI less than 18.5 kg/m2 (aOR 0.1; 95% 
CI 0.0–0.7) was identified as a negative predictor. However, the 
use of parenteral agents was not associated with sustained 



















Table 4. Treatment regimen and response for patients treated for 
M. abscessus and M. massiliense lung diseases 
 
M. abscessus  
(n = 19)a 
M. massiliense  
(n = 17)a 
P value 














Initial treatment regimen 
Macrolide with  
parenteral agentsb 
Macrolide with or without 




























Surgical treatment 3 (15.8%) 2 (11.8%) 1.000 
Treatment duration, weeksc 
Total duration of treatment 
Use of amikacin 
Use of cefoxitin 
















Initial culture conversion 
No. of patients achieving 
culture conversion 

































Abbreviations: AFB, acid-fast bacilli 
a Among patients with disease progression, 19 of 21 patients with M. abscessus 
lung disease and 17 of 21 patients with M. massiliense lung disease received 
treatment.  
b Parenteral agents included amikacin, cefoxitin, or imipenem, while oral agents 
included fluoroquinolone, amoxicillin/clavulanate, rifampin, or ethambutol.  
c Treatment duration and time to initial negative conversion were described as 





Figure 4. Kaplan-Meier analysis of the comparison of time to 
culture conversion between M. abscessus and M. massiliense lung 
diseases.   
Patients with M. massiliense lung diseases were significantly 
more likely to achieve initial culture conversion compared to 










Table 5. Predictors of sustained culture conversion among the 36 
patients treated for M. abscessus or M. massiliense lung disease 
 Unadjusted Adjusted 
Variables 
Odds ratio  
(95% CI) 
P value 
























































































































Abbreviations: BMI, body mass index; AFB, acid-fast bacilli; NTM, 
nontuberculous mycobacteria  
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5. Mediation analysis 
The causative organism’s susceptibility to clarithromycin was 
shown to be a significant predictive factor of sustained culture 
conversion (aOR 27.5; 95% CI 3.9–193.5). Since strains of M. 
abscessus and strains of M. massiliense showed a significant 
difference in the susceptibility to clarithromycin, we performed 
mediation analysis and tested the susceptibility to clarithromycin 
as a mediator of treatment outcomes. We adjusted the mediation 
analysis model with the BMI and the use of azithromycin rather 
than clarithromycin, which were identified as predictive factors 
of sustained culture conversion. As a result, the effect of 
infection with M. abscessus or M. massiliense on the treatment 
outcomes was shown to be significantly mediated by the 
susceptibility of the isolated strain to clarithromycin (indirect 
effect 0.28; CI 0.08–0.95). The proportion of the indirect effect 









The comparison of M. abscessus and M. massiliense lung 
diseases in our study revealed several interesting findings. First, 
the disease progression rate did not differ between the two 
groups during the follow-up period. Instead, lower BMI, bilateral 
lung involvement, and fibrocavitary type disease were predictive 
of disease progression. Second, better treatment response was 
observed for M. massiliense lung diseases, which is consistent 
with previous reports [13, 15, 16]. It is worth noting that this 
difference in treatment outcomes between M. abscessus and M. 
massiliense lung diseases was only partly mediated by their 
different susceptibilities to clarithromycin. Third, azithromycin 
showed superior efficacy in achieving sustained culture 
conversion compared with clarithromycin.  
The natural history of NTM lung diseases remains elusive, 
which makes it difficult to decide when to initiate treatment [26]. 
Mycobacterial virulence and host factors influence the 
progression of NTM lung diseases [18]. For MAC lung diseases, 
patients with M. intracellulare lung diseases were reported to be 
more likely to receive antibiotic therapy and have unfavorable 
microbiologic response after treatment compared with those with 
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M. avium lung diseases [27]. However, our study showed no 
difference in disease progression rate between M. abscessus and 
M. massiliense lung diseases, which suggests that these two 
species may not differ in virulence in spite of their difference in 
treatment response. Instead, clinical characteristics such as 
lower BMI and the radiographic pattern of involvement appear to 
be associated with disease progression. These findings are 
similar to those reported for MAC lung diseases [28-30]. 
For patients who received treatment for M. abscessus complex 
lung diseases, patients infected with M. massiliense rather than 
M. abscessus were more likely to have sustained culture 
conversion, which was consistent with previous studies [13, 15, 
16]. It has been suggested that the better treatment response 
observed for M. massiliense lung diseases is attributable to M. 
massiliense isolates rarely having inducible resistance to 
clarithromycin, and their more frequent susceptibility to 
macrolides [12, 15, 31]. However, according to the mediation 
analysis carried out in our study, this difference in susceptibility 
to clarithromycin accounted for only about 40% of the difference 
in treatment outcomes. This means that microbiologic factors 
other than susceptibility to clarithromycin as well as host factors 
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influence treatment outcomes. Whole genome sequencing and 
analysis of the causative mycobacteria could therefore play a 
role in identifying additional markers that may help to explain the 
different treatment outcomes observed between the two species.  
We determined several factors, including BMI and choice of 
macrolide, that influenced treatment outcomes. Lower BMI is a 
well-known factor associated with the development and/or 
progression of various chronic lung diseases and several 
infectious diseases [32-34]. However, our study is the first to 
report the superiority of azithromycin to clarithromycin in terms 
of achieving sustained culture conversion in patients with M. 
abscessus complex lung diseases. In MAC lung diseases, no 
difference was reported in treatment efficacy between these two 
drugs [35]. The reasons why azithromycin showed better 
response in our study is unclear, but the superiority of 
azithromycin in preventing inducible resistance may provide an 
explanation [31]. However, another study found no difference in 
terms of inducible resistance between these two agents, leaving 
some controversy around this issue [12]. Another possible 
explanation may lie in the different anti-inflammatory or 
immunomodulatory effects of these macrolides, but these 
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pharmacologic differences have not been consistent in previous 
reports [36, 37]. The longer half-life and improved tissue 
penetration of azithromycin could also explain the higher 
treatment efficacy of this drug [38]. 
Although ATS/IDSA guideline recommended the use of 
parenteral agents as well as macrolide treatment [18], in our 
study, the use of parenteral agents did not increase the chance 
of achieving sustained culture conversion. Longer treatment 
periods with parenteral agents than those used in our study may 
be needed to improve outcomes. However, such longer treatment 
periods would be impractical because of adverse drug reactions, 
inconvenience to patients, and increased costs. The observation 
that four out of seven patients (all four patients with M. 
massiliense lung diseases) for whom azithromycin or 
clarithromycin was prescribed without parenteral agents 
achieved sustained culture conversion, also raises a question on 
the role of using parenteral agents, especially for M. massiliense 
lung diseases. Recent report showing no difference in treatment 
outcomes between shorter and longer use of parenteral agents 
for the treatment of M. massiliense lung diseases further 
empathizes this issue [39].  
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The current study has several limitations. First of all, the 
initiation of treatment was determined by the duty physician. 
Although this decision was made taking account of radiographic 
and symptomatic changes, the subjective judgment of the 
physicians may have introduced bias. Second, several patients 
refused admission and did not receive parenteral therapy. 
Although this introduced variations to the predefined treatment 
protocol, it also enabled us to compare treatment response 
between patients who received parenteral therapy with those 
who did not. Third, only microbiologic response was assessed as 
a treatment outcomes in this study. Considering the chronic 
course of disease, improvement in patient quality of life as well 
as their length of survival may be more appropriate treatment 
response targets for M. abscessus complex lung diseases, as was 
illustrated by a recent study [40]. Finally, the small number of 
patients included in this study limited the statistical power of the 
analysis. A nationwide multi-center study should be performed 






In conclusion, the progression rates of M. abscessus lung 
diseases and M. massiliense lung diseases were similar but 
treatment outcomes were better for patients with M. massiliense 
lung diseases. Lower BMI, bilateral lung involvement, and 
fibrocavitary type disease were identified as predictors of 
disease progression. Among those patients who underwent 
treatment, infection with M. massiliense rather than M. 
abscessus and the use of azithromycin rather than clarithromycin 
were associated with sustained culture conversion. The 
difference in treatment outcomes observed for these two species 
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서론: 비결핵 항산균 폐 질환 중 Mycobacterium abscessus complex 에 
의한 폐 질환은 치료가 어렵고 예후가 좋지 않은 것으로 알려져 있다. 
M. abscessus complex 는 미생물학의 발전으로 최근 M. abscessus, M. 
massiliense, 그리고 M. bolletii 라는 3 가지 다른 균으로 이루어져 
있다는 것이 밝혀졌으며, 국내에서는 이 중 M. abscessus 와 M. 
massiliense 가 대부분을 차지하고 있다. 본 연구는 M. abscessus 폐 
질환과 M. massiliense 폐 질환의 질병의 진행 양상 및 치료 성적을 
비교 고찰하고자 하였다.  
 
방법: 서울대학교 병원에서 2006 년 1 월부터 2015 년 6 월 사이의 기간 
동안 진단된 56 명의 M. abscessus 폐 질환 환자와 54 명의 M. 
massiliense 폐 질환 환자의 의무 기록을 검토 및 분석하였다. 치료를 
필요로 할 수준으로 질병이 진행하는 데 걸리는 시간, 그리고 질병이 
진행하여 치료를 시행하였을 때 치료 성적을 양 군에서 비교하였다. 
또한 그 외에 질병의 진행 여부와 치료를 하였을 때 배양 음전 여부를 
예측할 수 있는 관련 인자를 확인하고자 하였다. 마지막으로 M. 
abscessus 와 M. massiliense 사이 치료 성적의 차이가 양 균 사이의 
Clarithromycin 감수성 차이에 의해 매개되는지를 분석하였다.  
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결과: M. abscessus 폐 질환 환자 중에서는 56 명 중 21 명에서, 그리고 
M. massiliense 폐 질환 환자 중에서는 54 명 중 21 명에서 임상적으로 
치료를 필요할 정도로 폐 질환이 진행 및 악화되었다. 양 군에서 
질병이 진행하는 데까지 걸리는 시간은 유의한 차이가 없었다. 대신 
진단 당시 낮은 체질량 지수, 양측 폐 침범, 그리고 섬유공동형 
질환이 질병의 진행을 예측할 수 있는 인자로 확인되었다. 폐 질환의 
진행 속도에는 차이가 없었지만, 질환이 진행하여 치료를 시행하였을 
때에는 M. massiliense 폐 질환에서 M. abscessus 폐 질환에 비하여 배양 
음전이 지속적으로 유지되는 치료 성공률이 유의하게 높았다. 이러한 
치료 성적의 차이는 부분적으로 양 균의 Clarithromycin 감수성 차이에 
의해 부분적으로 매개된다는 것을 확인할 수 있었으며, 그 외에 초 
치료 약제로 Clarithromycin보다는 Azithromycin을 사용하였을 때 배양 
음전을 유의하게 더 많이 이룰 수 있었다.  
 
결론: M. abscessus 폐 질환과 M. massiliense 폐 질환의 진행 속도는 비
슷하였다. 그러나 질병이 진행하여 치료를 시행하게 되었을 때에는 M. 
massiliense 폐 질환이 M. abscessus 폐 질환에 비해 치료 성적이 우수하
였다. 이러한 치료 성적의 차이는 양 균 사이의 Clarithromycin 감수성 
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